Document is current
Any future updates will be listed below
-
Authors
Strzelczyk, Adam https://orcid.org/0000-0001-6288-9915
Schubert-Bast, Susanne https://orcid.org/0000-0003-1545-7364
-
Funding
Funding for this research was provided by:
Projekt DEAL
- License Information
-
More Information
Article History
Accepted: 12 December 2020
First Online: 21 January 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. The authors did not receive funding for the preparation of this article.
: A. Strzelczyk reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, LivaNova, Marinus Pharmaceuticals, Medtronic, UCB Pharma and Zogenix. S. Schubert-Bast reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals, LivaNova, UCB Pharma and Zogenix.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors reviewed the literature, drafted the manuscript, generated the figures, and assume full responsibility for the final publication.
